JP2009007323A - Virus inactivation agent, method for preventing viral infection and container holding the virus inactivation agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new virus inactivation agent which can be safely used and exhibits high inactivation effect on viruses in a short time, and to provide a viral infection preventing method and a container. <P>SOLUTION: The invention provides a virus inactivation agent containing a persimmon extract as an active component, a viral infection preventing method and a container 10. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention is a virus inactivating agent derived from a natural product, and particularly contains a virus inactivating agent excellent in inactivating effect against caliciviruses such as Norovirus (Caliciviridae), a method for preventing virus infection, and the virus inactivating agent. Relates to the container to obtain.

  Recently, virus infection has become a problem as one of the causes of food poisoning. Among them, caliciviruses such as norovirus are likely to infect humans even in the winter, causing symptoms of food poisoning such as diarrhea and vomiting, and have strong infectivity, and therefore an effective prevention method is desired.

  However, calicivirus has a strong resistance to drugs, and it is difficult to kill with ethanol and chlorinated drugs, which are general-purpose disinfectants, and is not sufficient to prevent infection.

  On the other hand, although it has been reported that sterilization with 300 ppm or more of sodium hypochlorite is effective, sodium hypochlorite has problems in terms of use such as rusting of the metal and skin irritation. is there.

  Under such circumstances, investigations have been made on ingredients that have an excellent inactivation effect against viruses and can be used safely. For example, it comprises a solution containing a predetermined amount of a polyhexamethylene biguanide compound, a disinfectant having an alkaline pH (see Patent Document 1), and a virus growth inhibitor comprising a pepper powder or extract as an active ingredient (patent) Reference 2)) is said to have an inhibitory effect on feline calicivirus.

JP 2007-45732 A (page 1-14) Japanese Patent Laying-Open No. 2005-143391 (page 1-8)

  However, the disinfecting solution described in Patent Document 1 is limited to use at a low concentration from the viewpoint of safety to the skin, and has a great influence on pH to obtain virus inactivation, and is formulated as a preparation. There is also a restriction. On the other hand, the virus growth inhibitor described in Patent Document 2 requires a reaction for 30 minutes upon inactivation, and the inactivation rate is not sufficient.

  In addition, it is necessary to provide a spray device or a container or the like for safely and easily handling such a drug such as a virus inactive agent and easily.

  Therefore, the present inventors have provided a novel virus inactivating agent, a virus infection preventing method, and a virus inactivating agent that can be used safely and exhibit a high inactivation effect against viruses in a short time. The container which can also be stored is provided.

As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the cocoon extract exhibits an excellent inactivation effect against calicivirus, and has reached the present invention. That is, the virus inactivating agent according to the present invention comprises the following (1) to (6).
(1) A virus inactivating agent comprising a koji extract as an active ingredient.
(2) The virus inactivating agent according to (1), which contains alcohol.
(3) The virus inactivating agent according to (1) or (2), which contains an organic acid.
(4) The virus inactivating agent according to any one of (1) to (3), which is a liquid agent.
(5) The virus inactivating agent according to any one of (1) to (4), wherein the virus is calicivirus.
(6) A method for preventing viral infection, comprising spraying the virus inactivating agent according to any one of (1) to (5).

In addition, as a result of intensive studies, the present inventors need a container for safely and easily handling a preparation such as the virus inactivating agent having the constitutions (1) to (6) described above. And invented a container capable of storing such a virus inactivating agent. That is, the container which can also store the virus inactivating agent according to the present invention comprises the following (7) to (9).
(7) A container that has a mouth and has a medicine container that contains medicine and a cap having an outer cylinder and an inner cylinder fitted to the mouth, and can also store a virus inactivating agent. In
In the inner cylinder, slits are intermittently formed in the circumferential direction along the axial direction thereof, and a screwing projection for screwing into the mouth portion is formed on the inner peripheral surface of the inner cylinder. A container formed over the circumferential direction.
(8) The container according to (7), wherein a scale design is provided on at least one of the outer cylinder and the inner cylinder of the cap.
(9) The container according to (7) or (8), wherein the screwing protrusion functions as the scale design.
(10) The virus inactivating agent according to any one of (1) to (5) is stored in the drug storage unit, (7) to (9), Container.

  Since the virus inactivating agent of the present invention can inactivate 90% or more of calicivirus in about 30 seconds to 1 minute, virus infection can be effectively prevented in a short time. Moreover, since it is derived from natural products, it can be safely used as a method for preventing virus infection without causing skin irritation. Furthermore, it is effective in preventing food poisoning because of its excellent bactericidal effect such as Escherichia coli.

  Moreover, in the container of this invention, the screwing protrusion currently formed in the inner cylinder of a cap is used for attachment or detachment with the opening | mouth part of a chemical | medical agent storage part. At this time, since the slits are intermittently provided in the circumferential direction along the axial direction of the inner cylinder, the inner cylinder can be elastically deformed by the slits, and the stress at the time of attachment / detachment is concentrated in one place. Without being distributed throughout the inner cylinder. Thereby, damage, such as a crack of the inner cylinder accompanying use, can be prevented and durability as a cap can be improved.

  Further, in the container of the present invention, when the cap is used as a measuring cup, the medicine is poured into the inner cylinder and the outer cylinder almost uniformly through the slit. Without worrying, the amount of the medicine can be easily measured by pouring the medicine into the cap while looking at the scale design. Moreover, since the inner cylinder does not serve as a partition, it is easy to pour the medicine as the entire cap.

  In addition, the container of the present invention can improve visibility by allowing the screw projection to function as a scale design, and it is not necessary to provide a scale design in another place, so that the manufacturing cost can be suppressed. it can.

  In addition, the container of the present invention can be used safely by storing a medicine such as a virus inactivating agent in the medicine container, and prevents damage such as cracking of the inner cylinder of the cap associated with the use of the container. Thus, durability can be enhanced, and it can be stored and used safely and conveniently.

  As used herein, a virus inactivating agent means removing or significantly reducing the ability of a virus to infect or propagate. The virus inactivating agent of the present invention can target calicivirus as an inactivation target. Caliciviruses are classified into four types: Norovirus, Sapovirus, Lagovirus, and Vesivirus, and it is particularly preferable to inactivate Norovirus.

  As the koji extract, which is an active ingredient of the virus inactivating agent of the present invention, koji fruit juice or a koji fruit solvent extract can be used, and koji obtained from the fruit of oyster (Diospyros kaki Thunberg (Ebenaceae)). An extract is preferred. Moreover, you may use what is marketed and marketed as a koji extract, for example, brand name Pancil BA-200E-1 (made by a release scientific industry company), brand name Pancil PS-SP (made by a release science industry company), etc. Is mentioned.

  Since the virus inactivating agent of the present invention is derived from a natural product and has high safety, the liquid sputum extract may be treated as it is in a place where the virus is thought to exist, but more than necessary. In consideration of convenience, it is usually preferable to use an effective amount in a safe solvent such as water, alcohol or glycol.

  The concentration of the cocoon extract in the virus inactivating agent of the present invention is usually preferably 0.01% by mass or more, and more preferably 0.01 to 1% by mass. If the content of the cocoon extract in the virus inactivating agent is too small, the virus inactivating effect may not be sufficiently obtained, and if it is too much, the solubility of the cocoon extract cannot be obtained sufficiently, becoming turbid and precipitated. Etc. may occur, and the virus inactivation effect is not greatly improved.

  The virus inactivating agent of the present invention preferably contains an alcohol. Examples of the alcohol include ethanol, isopropanol, methoxybutanol and the like. The alcohol concentration in the virus inactivating agent of the present invention is usually preferably 20% by mass or more, and more preferably 20 to 99.9% by mass.

  Moreover, it is preferable that the virus activator of this invention contains an organic acid. Examples of the organic acid include malic acid, citric acid, succinic acid, tartaric acid, phytic acid, and the like. The concentration of the organic acid in the virus inactivating agent of the present invention is usually preferably 0.01% by mass or more, and more preferably 0.03 to 0.5% by mass.

  Although it is said that ethanol alone is not effective against norovirus, it improves the inactivation effect against viruses through synergistic action by using cocoon extract alone and alcohol and / or organic acid as well as cocoon extract alone. In addition, the bactericidal effect on fungi such as Escherichia coli such as O-157, Pseudomonas aeruginosa, Staphylococcus aureus, and black mold can be improved.

  As a preferable aspect of the virus inactivating agent of the present invention, for example, a cocoon extract 0.01 to 1% by mass, ethanol 20 to 99.9% by mass, malic acid 0.03 to 0.1% by mass, and It is preferable to add a purified water as appropriate to obtain a liquid adjusted to a total amount of 100% by mass.

  For example, the liquid (medicine) prepared as described above is preferably used in the form of liquid or liquid droplets as required, as an aerosol, hand spray, electric sprayer liquid, or the like. In addition to this, the above liquid agent may be impregnated into a non-woven fabric or chemical fiber substrate instead of a dust cloth, or a kit used by spraying, impregnating, etc., the above liquid agent on the above base material at the time of use. preferable.

The virus inactivating agent of the present invention is preferably sprayed as an aerosol agent, a hand spray agent or the like so that it is usually about 10 to 50 ml / m ^{2 at} the intended place of use.

  The virus inactivating agent of the present invention can be used as a preparation imparted with the desired effect by using various components in combination. For example, Moso bamboo extract, grapefruit, etc. Seed extract, yuzu seed extract, orange extract, flavonoid, green tea extract, rooibos tea extract, yucca extract, olive leaf extract powder, chitosan, oolong tea extract, grape seed extract, mullya extract, perilla oil, tea Dry distillate, Licorice oil extract, Moso bamboo dry extract, Perilla extract, Mustard extract, Broccoli powder, Ginger extract, Egonia extract, Kawara mugwort extract, Hoonoki extract, Forsythia extract, Momiji extract, Pepper Various plant extractions such as extract, citrus seed extract, raw soybean extract, pimenta extract, fruit extract, fruit seed extract It may be used one or more objects.

  Further, propellants such as liquefied petroleum gas, dimethyl ether, compressed gas, POE alkyl ether, POE hydrogenated castor oil, POPPOE copolymer, polyoxyalkylene alkyl ether, POE sorbitan fatty acid ester, glycerin fatty acid ester, POE fatty acid ester, POE alkyl Surfactants such as amines, stabilizers such as ascorbic acid and butylhydroxyanisole, paraoxybenzoates, quaternary ammonium salts, preservatives such as phenoxyethanol, allergen inactivators such as catechins, photocatalysts such as fine titanium oxide Further, a non-photocatalyst such as titania phosphate may be used.

  If necessary, insecticides and repellents (insect repellents) may be used in combination, for example, natural products such as natural pyrethrin, benzyl alcohol, mint oil, citronella oil, eucalyptus oil, geranium oil, and mosquito weeds. It is good to use the component derived from.

  In addition to the above components, the virus inactivating agent of the present invention may contain a fragrance as long as it does not inhibit the virus inactivating effect of the koji extract. Such a fragrance may be a natural fragrance, a synthetic fragrance, or a blended fragrance.

  Natural flavors include, for example, orange oil, lemon oil, grapefruit peel extract, grape peel extract, lime oil, petitgren oil, yuzu oil, neroli oil, bergamot oil, lavender oil, lavandin oil, abies oil, bay oil, Boa de Rose oil, Ylang Ylang oil, Citronella oil, Geranium oil, Peppermint oil, Spearmint oil, Eucalyptus oil, Lemongrass oil, Patchouli oil, Jasmine oil, Rose oil, Cedar oil, Vetiver oil, Galvanum oil, Oak moss oil , Essential oils such as pine oil, camphor oil, melamine oil, turpentine oil, clove oil, clove leaf oil, cassia oil, nutmeg oil, cananga oil, thyme oil and the like.

  Synthetic fragrances include, for example, linalyl acetate, C6-C12 aliphatic aldehydes, phenylethyl alcohol, benzyl acetate, geranyl acetate, geranyl formate, vanillin, nitromusks, galaxolide, tonalide, pentalide, santarex, amyl salicylate, amyl Examples include acetate, γ-undecalactone, ethyl methylphenylglycidate, heliotropin and the like. Each of these fragrances may be used alone or as a blended fragrance prepared by mixing two or more kinds.

  In addition, the virus inactivating agent of the present invention may contain an antioxidant, a light stabilizer and the like for the purpose of stabilizing the koji extract. Examples of such an antioxidant include dibutylhydroxytoluene and dibutylhydroxyanisole. Examples of the light stabilizer include 2-hydroxy-4-methoxybenzophenone and 2- (2'-hydroxy-5'-methylphenyl) benzotriazole.

  As described in detail above, the virus inactivating agent of the present invention is derived from natural products and can be used safely, so it can be used safely in kitchens, sinks, refrigerators and other food handling areas, living rooms such as living rooms and bedrooms, curtains and bedding. Etc. can be used. Furthermore, it may be used for toilets, toilets, bathtubs, washstands, air conditioners, air purifiers, and the like, where viruses and germs can easily propagate.

  Hereinafter, a preferred embodiment of a container that can also contain a drug such as a virus inactivating agent of the present invention will be described with reference to the drawings.

  1 to 3 show an embodiment of a container according to the present invention. FIG. 1 (a) is a partially broken front view of the container according to an embodiment of the present invention, and FIG. 2 is a partially broken external perspective view of the cap of FIG. 1B, FIG. 3 is a partially broken external perspective view showing another modification of the cap according to the present invention, and FIG. These are the perspective views of the spraying apparatus which concerns on other embodiment of this invention.

  As shown in FIG. 1A, a container 10 according to an embodiment of the present invention includes a medicine storage unit 11 and a cap 12.

  The medicine container 11 has an edge 13 near the upper end, and a cylindrical mouth 14 at the center. A male screw portion 15 having a string winding shape of a screw is formed as a thread valley portion on the outer periphery of the mouth portion 14.

The cap 12 is made of resin and is formed in a cylindrical shape, and is fitted to the outer tube 16 having the top plate 17 and the mouth portion 14. Therefore, the cap 12 is attached to the top plate 17 on the inner peripheral side of the outer tube 16. It is mainly composed of an inner cylinder 18 provided in combination.
In addition, the shape of the outer cylinder 16 of the cap 12 is not limited to the cylindrical shape, but can be changed to various shapes as necessary, such as a substantially triangular prism shape and a substantially rectangular shape.

  The inner cylinder 18 is formed with a screw projection 19 that functions as a female screw to be screwed into the male screw part 15 of the medicine container 11 on the inner peripheral surface thereof.

When the cap 12 is rotated in the clockwise direction, the screw projection 19 is screwed into the male screw portion 15 in the mouth portion 14 of the medicine storage portion 11 and is assembled to the medicine storage portion 11. On the contrary, the screw projection 19 is removed from the male screw portion 15 by being rotated counterclockwise and removed from the medicine storage portion 11.
In addition, it is good to assemble packing as needed to the top plate 17 side of the inner cylinder 18 of the gap 12. In this case, the mouth portion 14 can be reliably sealed.

  As shown in FIG. 1B, the cap 12 has a positioning projection 21 connected to the top plate 17 on the inner periphery of the inner cylinder 18. The positioning protrusion 21 has an annular shape and is inserted into the mouth portion 14 of the medicine storage portion 11 to position the cap 12 on the mouth portion 14.

  The cap 12 is formed with a pair of slits (the other slit 22 is shown in FIG. 2) 22 in the inner cylinder 18. The slits 22 are intermittently formed in the circumferential direction along the axial direction of the inner cylinder 18 at intervals of approximately a half circumference, and have a length from the top plate 17 side to the tip of the inner cylinder 18. .

  The screw projection 19 is continuously formed on the inner peripheral surface 23 of the inner cylinder 18 so as to be bridged by the slit 22.

  As shown in FIG. 2, the cap 12 is used upside down from the state of FIGS. 1A and 1B when used as a measuring cup.

The cap 12 is provided with a scale design 25 on the inner peripheral surface 24 of the outer cylinder 16. The scale design 25 is used as a guide for a single use amount of the medicine by injecting the medicine stored in the medicine storage section 11 into the cap 12 after the cap 12 is removed from the medicine storage section 11. Used for.
Here, the amount used once is the total amount up to the scale design 25 inside the inner cylinder 18 including the positioning protrusion 21 and inside the outer cylinder 16 communicated by the slit 22.

  At this time, since the screw projection 19 of the inner cylinder 18 is arranged in a scale at a position that is easily visible to the user, if the screw projection 19 is aligned with the scale design 25, for example, the cap 12 is attached. The amount of the medicine can be measured by looking at the screw projection 19 in place of the scale design 25 without being inclined.

  Such a container 10 is used, for example, as a form in which a medicine such as the virus inactivating agent described above is also housed in the medicine housing portion 11 and a cap 12 is attached. Then, the user can remove the cap 12 from the medicine container 11, remove a lid member such as a virgin seal, inject the medicine into the cap 12, and use it appropriately. For example, it is possible to appropriately prevent a virus by applying a medicine to various places with a drug included.

  As described above, according to the container 10 according to the embodiment of the present invention, the screwing protrusion 19 formed on the inner cylinder 18 of the cap 12 is used for attaching to and detaching from the mouth part 14 of the medicine container 11. It is done. At this time, since the slit 22 is intermittently provided in the circumferential direction along the axial direction of the inner cylinder 18, the inner cylinder 18 can be elastically deformed by the slit 22, and the stress at the time of attachment / detachment is reduced. Dispersed throughout the inner cylinder 18 without concentrating on the location. Thereby, damage, such as a crack of the inner cylinder 18 accompanying use, can be prevented and durability as the cap 12 can be improved.

  Further, according to the container 10, when the cap 12 is used as a measuring cup, a medicine such as a virus inactivating agent is poured almost uniformly into the inner cylinder 18 and the outer cylinder 16 through the slit 22. Therefore, the amount of the medicine can be easily measured while looking at the scale design 25 without worrying about the distinction between the inner cylinder 18 and the outer cylinder 16. Moreover, since the inner cylinder 18 does not become a partition, the cap 12 can be poured as a whole because the medicine can be charged.

  Moreover, according to the container 10, since the screwing protrusion 19 functions as a scale design, the visibility can be improved, and it is not necessary to provide a scale design in another place, thereby suppressing the manufacturing cost. Can do.

  Moreover, according to the container 10, since medicines, such as a virus inactivating agent, are also accommodated in the medicine accommodating part 11, it can be used safely, that is, the crack of the inner cylinder 18 of the cap 12 accompanying use of the container 10, etc. Can be stored and used safely and conveniently.

  In addition, this invention is not limited to embodiment mentioned above, A deformation | transformation, improvement, etc. are possible suitably.

In addition, the material, shape, dimension, numerical value, form, number, arrangement location, and the like of each component in the above-described embodiment are arbitrary and are not limited as long as the present invention can be achieved.
For example, as shown in FIG. 3, as a modification of the above-described container cap 112, the slits 122 may be formed intermittently at four locations at intervals of ¼ circumference in the circumferential direction. 1 place, 3 places, 5 places or more can be formed as necessary, but in any case, it may be formed at equal intervals in the circumferential direction.
In the above-described embodiment, the screw projection (19) is described as being formed continuously with the inner peripheral surface (23) of the inner cylinder (18) so as to be bridged with the slit (22). However, the present invention is not limited to this, and the screw projection 119 may be formed intermittently without bridging the slit 122 as shown in FIG.
Further, in the above-described embodiment, the scale design (25) is provided on the inner peripheral surface (24) of the outer cylinder (16). However, the present invention is not limited to this, and as shown in FIG. 125 may be provided on a part of the outer peripheral surface of the inner cylinder 18. In this case, visibility is increased, which is preferable.

  Furthermore, as a container used for spraying the virus inactivating agent of the present invention, the spray device 30 shown in FIG. 4 can be exemplified as another embodiment.

As shown in FIG. 4, a hand spray type spraying device 30 exemplified as a container for storing the virus inactivating agent of the present invention includes a hollow substantially cylindrical drug storage portion 31 and an upper end portion of the drug storage portion 31. A spray means (not shown) is provided in the vicinity of the center of the medicine container 31 so as to project along the axial direction of the medicine container 31 and is tilted to spray the medicine in the medicine container 31, and an upper end of the medicine container 31. And an attached cap 32. The cap 32 is attached to the medicine container 31 by a screw member 34.
And the cap 32 has the trigger 35, The virus inactivation agent accommodated in the chemical | medical agent storage part 31 is sprayed by the trigger 35 being pulled.

  EXAMPLES The present invention will be described in more detail with reference to examples below, but the present invention is not limited to these examples.

Test example 1
In order to confirm the effect of the virus inactivating agent of the present invention, a virus inactivation test was performed as follows.
<Test method>
1) Test specimen The test specimen shown in Table 1 was prepared and used. Moreover, brand name Pancil BA-200E-1 (made by a release scientific industry company) was used as a koji extract.

2) Test virus Feline calicivirus vaccine strain

3) Cells used CRFK cells (Dainippon Pharmaceutical Co., Ltd.)

4) Medium used (1) Cell growth medium A medium obtained by adding 10% newborn calf serum to Eagle MEM (containing 0.06 mg / ml kanamycin) was used.
(2) Cell maintenance medium Eagle MEM supplemented with 2% newborn calf serum

5) Preparation of virus suspension (1) Cell culture Using cell growth medium, the used cells were cultured in a single layer in a tissue culture flask.
(2) Inoculation of virus After the monolayer culture, the cell growth medium was removed from the flask and inoculated with the test virus. Next, the cell maintenance medium was added and cultured in a carbon dioxide incubator (CO2 concentration: 5%) at 37 ° C. ± 1 ° C. for 2 days.
(3) Preparation of virus suspension After culturing, cell morphology was observed using an inverted phase contrast microscope, and it was confirmed that morphological change (cytopathic effect) occurred in the cells. Next, the culture solution was centrifuged (3000 r / min, 10 minutes), and the resulting supernatant was used as a virus suspension.

6) Test procedure 0.1 ml of the virus suspension was added to 1 ml of the test sample and mixed to obtain a working solution. It was allowed to act at room temperature and diluted 10-fold with cell maintenance medium after 30 seconds and after 1, 5, 10, and 15 minutes of action. Purified water was similarly tested as a control test solution, and measurement was performed at the start and after 15 minutes.

7) Measurement of virus infectivity titer Using the cell growth medium, the used cells were cultured in a monolayer in a tissue culture microplate (96 wells), and the cell growth medium was removed and 0.1 ml of cell maintenance medium was added. Next, 0.1 ml of the working solution dilution was inoculated into each well, and cultured for 7 days in a carbon dioxide incubator (CO2 concentration: 5%) at 37 ° C. ± 1 ° C. After culturing, the presence or absence of morphological changes (cytopathic effect) of cells was observed using an inverted phase contrast microscope, and the 50% tissue culture infectious dose (TCID50) was calculated by the Reed-Muench method, and the virus infection per ml of working fluid Converted to the price.

<Test results>
From the measured value of the working fluid shown in Table 2 (TCID50), the virus inactivation rate (%) of the test sample was calculated by the following formula. The results are shown in Table 3.
Formula: Inactivation rate (%) = 100−Measurement time TCID50 ÷ Start time TCID50 × 100

  As can be seen from Table 2, the test sample was able to significantly reduce the infectivity of feline calicivirus in a short time. Further, as can be seen from Table 3, the test specimen showed an inactivation rate of 90% or more after 30 seconds, 95% or more after 1 minute, and almost 100% after 10 minutes.

  From these results, it can be seen that the virus inactivating agent of the present invention containing the koji extract can exert a high inactivating effect in a short time against caliciviruses such as norovirus and is effective in preventing infection of calicivirus. confirmed.

Test example 2
In order to confirm the bactericidal effect of the virus inactivating agent of the present invention against Escherichia coli, a bactericidal test was performed as follows.
[Test method]
1) Test specimens Test specimens described in Table 1 were prepared and used.
2) Test strain E. coli, serotype O-157; H7, verotoxin I and type II producing strain (Escherichia coli ATCC 43895)
3) Medium for measuring the number of bacteria and medium conditions SCDLP agar medium (manufactured by Nippon Pharmaceutical), pour plate culture method, 35 ° C. ± 1 ° C., 2 days.
4) Preparation of test bacterial solution After culturing the test strain on a normal agar medium (manufactured by Eiken Chemical Co., Ltd.) at 35 ° C. ± 1 ° C. for 18-24 hours, it was suspended in physiological saline, and the bacterial count was about 107 / ml. This was prepared as a test bacterial solution.
5) Test operation 0.1 ml of the test bacterial solution was inoculated into 10 ml of the test sample to prepare a test solution. After storing at room temperature and after 30 seconds and 1, 5, 10, 15 minutes, 1 ml of the test solution was added to 9 ml of the SCDPL medium, and the number of viable bacteria in the test solution was measured using a medium for measuring the number of bacteria.
In addition, as a control, the same test was performed using purified water, and the viable cell count was measured at the start and after 15 minutes.
[Test results]
From the measured number of viable bacteria described in Table 4, the bactericidal rate of the test specimen was calculated by the following formula. The results are shown in Table 5.
Formula: Bactericidal rate (%) = 100-viable cell count at measurement / viable cell count at start × 100

  As can be seen from Table 4, the test specimen showed high bactericidal activity against E. coli. Further, as can be seen from Table 5, it was confirmed that the test specimen had a bactericidal rate of almost 100% after 30 seconds against E. coli. That is, it was found that the virus inactivating agent of the present invention containing the koji extract has an inactivating effect on calicivirus and has a remarkable bactericidal power against fungi such as Escherichia coli in a short time.

(A) is a partially broken front view of the container which concerns on one Embodiment of this invention, (b) is sectional drawing of the cap in the container of (a). It is a partially broken external appearance perspective view of the cap of FIG.1 (b). It is a partially broken external appearance perspective view which shows the other modification of the cap which concerns on this invention. It is a perspective view of the spraying device concerning other embodiments of the present invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 10 Container 11 Drug storage part 12 Cap 16 Outer cylinder 18 Inner cylinder 19 Screw projection 22 Slit 25 Scale design 30 Aerosol spray device 31 Drug storage part 32 Cap 34 Screw member 35 Trigger 36 Nozzle

Claims (9)

  Virus inactivating agent containing cocoon extract as an active ingredient.   The virus inactivating agent according to claim 1 containing alcohol.   The virus inactivating agent according to claim 1 or 2, comprising an organic acid.   The virus inactivating agent according to any one of claims 1 to 3, which is a liquid agent.   The virus inactivating agent according to any one of claims 1 to 4, wherein the virus is calicivirus.   A method for preventing viral infection comprising spraying the virus inactivating agent according to any one of claims 1 to 5. In a container that can store a virus inactivating agent, comprising a medicine storage part that has a mouth part and stores a medicine, and a cap that has an outer cylinder and an inner cylinder fitted to the mouth part,
In the inner cylinder, slits are intermittently formed in the circumferential direction along the axial direction thereof, and a screwing projection for screwing into the mouth portion is formed on the inner peripheral surface of the inner cylinder. A container formed over the circumferential direction. The container according to claim 7, wherein a scale design is provided on at least one of the outer cylinder and the inner cylinder of the cap.   The container according to claim 7 or 8, wherein the screw projection functions as the scale design.

Images